ArticleEndocrinology, diabetes & metabolism2026
Comparative Efficacy and Safety of Saroglitazar and Dapagliflozin on Hepatic Steatosis and Glycemic Control in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A 25-Week Prospective Multicenter Comparative Cohort Study.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease globally, driven by rising obesity and type 2 diabetes mellitus (T2DM). Existing medications provide minimal fibrosis regression, highlighting the need for comparative evidence on agents with metabolic and hepatic benefits. This study compared the efficacy and safety of saroglitazar 4 mg and dapagliflozin 10 mg in patients with MASLD.
methodsThis 25-week, prospective, multicentre, open-label active-controlled comparative cohort study enrolled adults aged 18-70 years with MASLD confirmed by FibroScan (steatosis grade S3, controlled attenuation parameter [CAP] ≥ 292 dB/m, and/or fibrosis stage ≥F2, liver stiffness measurement [LSM] ≥ 8.0 kPa). Participants received saroglitazar (n = 27) or dapagliflozin (n = 27) once daily, added to standard of care per physician discretion. The primary endpoint was change from baseline in hepatic steatosis (CAP) and fibrosis (LSM); secondary endpoints included HbA1c, hepatic enzymes, lipid profile, and adverse events.
resultsAll 54 participants completed follow-up. CAP decreased from 314.7 to 278.7 dB/m with saroglitazar and from 310.2 to 287.0 dB/m with dapagliflozin (between-group p = 0.44). LSM decreased in both arms (saroglitazar -0.96 kPa; dapagliflozin -0.46 kPa; between-group p = 0.80). HbA1c improved in both groups (saroglitazar 8.28%-6.76%; dapagliflozin 8.14%-7.30%), with a significantly greater reduction with saroglitazar (between-group p = 0.04). ALT and AST declined similarly in both arms despite higher baseline ALT with saroglitazar. Triglycerides decreased significantly within both groups (saroglitazar -62.5 mg/dL; dapagliflozin -28.3 mg/dL), with no significant between-group difference. No treatment-emergent adverse events, including edema, occurred in either group.
conclusionsBoth saroglitazar and dapagliflozin improved hepatic steatosis, fibrosis markers, liver enzymes, and glycemic control over 25 weeks, with comparable hepatic benefit. Saroglitazar produced a significantly greater reduction in HbA1c, suggesting a possible glycemic-preferential advantage in patients requiring simultaneous glycemic and hepatic control; larger randomized trials are needed to confirm any differential hepatic efficacy.
trial registrationClinical Trials Registry of India, CTRI/2024/08/071848.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.